Dr Jesse Goodman to retire after 9 years of service

杰西·古德曼博士在服务9年后将退休。

GSK plc (LSE/NYSE: GSK) has today announced that Dr Gavin Screaton will join the Board of the Company as a Non-Executive Director from 1 May 2025. Dr Screaton’s appointment follows a search to replace the skills and experience of Dr Jesse Goodman who steps down from the Board after the company’s Annual General Meeting in May 2025, after nine years of service..

GSK plc（伦敦证券交易所/纽约证券交易所代码：GSK）今天宣布，加文·斯克里顿博士将于2025年5月1日加入公司董事会，担任非执行董事。斯克里顿博士的任命是在寻找替代杰西·古德曼博士技能和经验的过程中确定的，古德曼博士在服务九年后，将于2025年5月公司年度股东大会后卸任董事会职务。

Dr Screaton is currently Head of the world-leading

斯克里顿博士目前是世界领先的负责人

1

1

Medical Sciences Division at the University of Oxford, and an expert in the field of immunology and infectious diseases, two areas of science critical to GSK.

牛津大学医学科学部，同时也是免疫学和传染病领域的专家，这两个科学领域对GSK至关重要。

Dr Screaton is a Fellow of the Academy of Medical Sciences, a Fellow of the Royal College of Physicians, and a former Senior Investigator at the National Institute for Health Research in the United Kingdom. He is also a Non-Executive Director of Oxford University Hospitals NHS Foundation Trust and a Trustee of the Jenner Vaccine Foundation.

Screaton博士是英国医学科学院院士、英国皇家内科医学院院士，曾任英国国家健康研究所高级研究员。他还是牛津大学医院NHS基金会信托的非执行董事和詹纳疫苗基金会的理事。

He also co-founded RQ Bio, a biotech company focused on development of preventative medicines to provide immunity and protection against viral infectious diseases..

他还共同创立了RQ Bio，这是一家专注于开发预防性药物以提供对病毒性传染病的免疫力和保护的生物技术公司。

On appointment, Dr Screaton will become a member of the GSK Board Science Committee and the Corporate Responsibility Committee.

斯克里顿博士在就任后将成为GSK董事会科学委员会和企业责任委员会的成员。

Sir Jonathan Symonds, Chair of GSK said,

葛兰素史克董事长乔纳森·赛蒙兹爵士表示，

“We are delighted to welcome Gavin to the Board of GSK. His deep expertise in immunology and infectious diseases, which are core areas of scientific research focus for GSK, together with his considerable experience in public health, will bring valuable perspective to the Board.

“我们非常高兴欢迎加文加入GSK董事会。他在免疫学和传染病方面的深厚专业知识，这是GSK科学研究的核心领域，加上他在公共卫生方面的丰富经验，将为董事会带来宝贵的视角。

The appointment will also help to replace the skillset and experience of Jesse Goodman who steps down from the GSK Board after nine years of service. As a former FDA Chief Scientist, the Board as a whole and the Science Committee in particular, has benefitted hugely from Jesse’s wealth of expertise in infectious diseases, regulation and public health.

此次任命还将有助于替换杰西·古德曼的技能和经验，他在服务九年后将退出GSK董事会。作为前FDA首席科学家，整个董事会，尤其是科学委员会，从杰西在传染病、监管和公共卫生方面的丰富专业知识中获益良多。

He has made a fantastic contribution to GSK and we wish Jesse all the very best for the future.”.

他对GSK做出了巨大的贡献，我们祝愿Jesse未来一切顺利。”

Notes:

注释：

The appointment of Dr Screaton was made by the Board on the recommendation of the Nominations & Corporate Governance Committee. The Committee conducted an extensive search and selection process for this appointment, using an external search firm, which is a signatory of the Voluntary Code of Conduct for Executive Search Firms.

董事会根据提名与公司治理委员会的推荐，任命了Screaton博士。该委员会为此次任命进行了广泛的搜索和筛选过程，使用了一家外部搜索公司，该公司是《高管搜索公司自愿行为准则》的签署方。

The external search firm provided a comprehensive list of candidates who were approached, evaluated and interviewed against an agreed set of criteria aligned to the Board’s target skills matrix. The Board satisfied itself that Dr Screaton had the experience and time available to carry out the role..

外部招聘公司提供了一份全面的候选人名单，这些候选人根据与董事会目标技能矩阵相符的一套标准被接触、评估和面试。董事会确信Screaton博士拥有担任该职位所需的经验和时间。

The Board has determined that Dr Screaton is an independent Non-Executive Director in accordance with the UK Corporate Governance Code.

董事会已确定Screaton博士根据《英国公司治理准则》为独立董事。

Dr Screaton will receive the standard basic fee for a Non-Executive Director of £122,258 per annum (including travel allowance). He will also receive fees of £30,000 per annum as a scientific and medical expert. Dr Screaton will be required to build towards a share ownership requirement of GSK shares in accordance with the Company’s shareholder approved Non-Executive remuneration policy..

Screaton博士将获得每年122,258英镑的标准非执行董事基本费用（含交通津贴），并作为科学和医学专家每年额外获得30,000英镑的费用。根据公司股东批准的非执行董事薪酬政策，Screaton博士还需逐步达到持有GSK公司股份的要求。

“Scientific and Medical Expert” - The Board designates Non-Executive Directors whose expertise or backgrounds as renowned medical scientists, researchers, or physicians mean that they can bring scientific or industry expertise to the Board’s deliberations.

“科学与医学专家”——董事会指定那些作为著名医学科学家、研究人员或医生拥有专业知识或背景的非执行董事，他们能够为董事会的审议带来科学或行业专业知识。

Dr Screaton does not have a service contract. He has a letter of appointment which may be viewed by contacting the Company Secretary at the Company’s registered office.

Screaton博士没有服务合同。他有一封任命书，可以通过联系公司注册办事处的公司秘书查看。

There are no further disclosures to be made in respect of Dr Screaton’s appointment under Listing Rule 6.4.8R

根据上市规则6.4.8R，关于Screaton博士的任命无需进一步披露。

As of 1 May 2025, the Board of GSK will comprise:

截至2025年5月1日，GSK董事会将包括：

Sir Jonathan Symonds

乔纳森·赛门兹爵士

Non-Executive Chair

非执行主席

Emma Walmsley

艾玛·沃尔姆斯利

Chief Executive Officer

首席执行官

Julie Brown

朱莉·布朗

Chief Financial Officer

首席财务官

Charles Bancroft

查尔斯·班克罗夫特

Senior Independent Non-Executive Director

高级独立董事

Elizabeth McKee Anderson

伊丽莎白·麦基·安德森

Independent Non-Executive Director

独立非执行董事

Dr Hal Barron

哈尔·巴伦博士

Non-Executive Director

非执行董事

Dr Anne Beal

安妮·贝阿尔博士

Independent Non-Executive Director

独立非执行董事

Wendy Becker

温迪·贝克尔

Independent Non-Executive Director

独立非执行董事

Dr Hal Dietz

哈尔·迪茨博士

Independent Non-Executive Director

独立非执行董事

Dr Jesse Goodman

杰西·古德曼博士

Independent Non-Executive Director

独立非执行董事

Dr Jeannie Lee

李珍妮博士

Independent Non-Executive Director

独立非执行董事

Dr Gavin Screaton

Gavin Screaton博士

Independent Non-Executive Director

独立非执行董事

Dr Vishal Sikka

维沙尔·西卡博士

Independent Non-Executive Director

独立非执行董事

About GSK

关于GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

GSK是一家全球生物制药公司，致力于联合科学、技术和人才，共同战胜疾病。欲了解更多信息，请访问gsk.com。

Cautionary statement regarding forward-looking statements

关于前瞻性声明的警示声明

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q4 Results for 2024..

GSK提醒投资者，GSK所做的任何前瞻性声明或预测，包括本公告中所包含的内容，均受可能导致实际结果与预测结果存在重大差异的风险和不确定性影响。这些因素包括但不限于GSK 2023年Form 20-F年度报告第3.D项“风险因素”中描述的内容，以及GSK 2024年第四季度财报中提及的信息。

References

参考文献

The University of Oxford is ranked first in Times Higher Education (THE) World University Rankings for Medicine, as of January 2025. This is the 14th consecutive year that Oxford has led the THE subject rankings in medicine.

截至2025年1月，牛津大学在《泰晤士高等教育》（THE）世界大学医学排名中位居第一。这是牛津大学连续第14年在THE医学学科排名中名列前茅。